...
首页> 外文期刊>Data in Brief >Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models
【24h】

Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models

机译:关于体外的数据,斜体>和在体内 italic>紫红素,紫杉醇和两个组合在HT-29和YM中的抗肿瘤作用-1癌细胞系和HT-29结肠癌异种移植模型

获取原文

摘要

Colon cancer is one of the fatal cancers in the world that metastatic potential and resistance to chemotherapy drugs are outstanding causes of cancer-induced mortality . We have investigatedin vitroandin vivoanti-cancer effect of itraconazole and paclitaxel alone and their anti-cancer synergistic effect through MTT assay in YM-1 and HT-29 cell lines and in HT-29 tumor-bearing nude mice. Histopathological experiment was done for further assessment. Also, we evaluated the inhibitory effect of itraconazole on P-gp using specificin vivobiodistribution through99mTc-MIBI uptake.99mTc-MIBI, a myocardial perfusion imaging agent, is a useful radiotracer in diagnosis of some tumors and the liver and tumor accumulation of99mTc-MIBI is changed by P-gp regulators . The data presented in this article are related to the research paper entitled “Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice”. We hope our preliminary data to be helpful to design the chemotherapy regimen schedule with Itraconazole and Paclitaxel.
机译:结肠癌是世界上致命癌症之一,即转移性潜力和对化疗药物的抗性是癌症诱导的死亡的突出原因。我们对Itraconazole和紫杉醇的vitroandinVivoanti-癌症作用仅通过YM-1和HT-29细胞系中的MTT测定和HT-29肿瘤裸鼠中的MTT测定来研究紫红素唑和紫杉醇的抗癌协同作用。完成组织病理学实验以进行进一步评估。此外,我们评估了Itraconazole对P-GP的抑制作用,使用SpeciolmibioPiodistibution通过199MTC-MIBI吐痰.99MTC-MIBI,一种心肌灌注成像剂,是一种有益的放射机构,用于一些肿瘤的诊断和肝脏和肿瘤积累的199mtc-mibi是P-GP稳压器改变。本文提出的数据与标题的研究文件有关,标题为“Itraconazole协同增加紫杉醇和99MTC-MIBI积累的治疗效果,作为P-GP活性的探针,在HT-29携带的裸鼠中”。我们希望我们的初步数据有助于使用Itraconazole和Parlitaxel设计化疗方案。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号